20 Tweets 7 reads Jan 15, 2023
#Chemcon Speciality Chemicals Ltd.
A Techno-Funda ๐Ÿงตon Chemcon Speciality Chemicals Ltd.(CSCL)
CMP - 290
Technical View ๐Ÿ‘‡
About :
Co. is manufacturer of speciality chemicals. They are:
๐Ÿ‘‰Only Manufacturer of HMDS in India & 3rd largest manufacturer Worldwide
๐Ÿ‘‰Only Manufacturer of Zinc Bromide in India
๐Ÿ‘‰Largest Manufacturer of CMIC Worldwide
๐Ÿ‘‰Largest Manufacturer of Calcium Bromide in India
Key Business Segments: ๐Ÿ‘‡
HMDS Applications in๐Ÿ‘‡
๐Ÿ‘‰Pharmaceuticals as a silylating agent in drugs manufacturing
๐Ÿ‘‰Semiconductor: Surface treatment agent of diatomite, white carbon black, titanium & blond additives of photoresist
๐Ÿ‘‰Organic Synthesis: Precursor to many bases common in organic synthesis
CMIC Applications in๐Ÿ‘‡
๐Ÿ‘‰mainly used in pharmaceutical industry as a key intermediate for anti-AIDS, anti-hepatitis B drug Tenofovir
๐Ÿ‘‰used in synthesis of other antiviral drugs
Oilwell Completion Chemicals
๐Ÿ‘‰Calcium Bromide- used as a completion & work-over fluid to control wellbore pressures in upstream oil & gas operations
๐Ÿ‘‰Zinc Bromide- used to prepare non-damaging liquids
๐Ÿ‘‰Sodium Bromide used to form clear workaround & drilling fluids.
REVENUE CONTRIBUTION:
HMDS - 51% revenue sare in FY22
CMIC โ€“ 26% revenue share in FY22
Bromides โ€“ 23% revenue share in FY22
Majorly Manufacturing Exports contributes to 37% from
USA, UAE
Japan, Italy
Spain, Russia
China, Malaysia
Germany, Thailand
& South Korea
KEY CLIENTELE :
๐Ÿ‘‰Long-Term healthy Relationships with Clients.
CHEMCON'S MARKET SHARE IN GLOBAL MARKET๐Ÿ‘‡
Manufacturing Units:๐Ÿ‘‡
๐Ÿ‘‰Co announced successful commencement of P9 facility by adding 2400 MTPA of Bromo Benzene product
๐Ÿ‘‰Co. guides to commence P-10 facility from FY24 which is currently under construction stage
๐Ÿ‘‰Co. acquired adjacent land which is for further expansion
UPDATE on CAPEX ๐Ÿ‘‡
FIANCIAL PARAMETERS :
Stock P/E - 15.6
Promotors holding - 74.5%
ROE- 16.3%
ROCE - 20.9%
Debt free Co.
Strong Uptrend in Profit after Tax YoY
KEY GROWTH DRIVERS
๐Ÿ‘‰Co product portfolio is well positioned to capitalize Import Substitute theme
๐Ÿ‘‰Co. is expanding its product PF by adding new products & new applications segment like Agro-Chem
๐Ÿ‘‰Co is also looking to reduce dependency on Chinese RM by backward integration
KEY RISKS :
High Customer Concentration: Almost 59% of the revenue is generated from the top 5 clients. Any Customer loss may affect significantly.
Dependency on China for procuring some of its raw materials.
Q2FY23 CONCALL UPDATE:
๐Ÿ‘‰Co. is procuring Raw Material for CMIC i.e, Methyl Chloroformate from Paushak on regular basis
๐Ÿ‘‰P10 is expected to complete in Mar'23, so that Co. can expect the product out in Q1 2024. The new unit is into import substitute for agro chemical as pharma
๐Ÿ‘‰Co's efforts towards increasing the product basket towards Agro-Chem also to take care of the volatility affecting entire business of the Co. coz of focus only Pharma.
๐Ÿ‘‰Mgmt is 100% confident that EBITDA per kg or may be gross profit per kg again moving to the normal level
๐Ÿ‘‰Mgmt expects that the Solar power plant commissioned at Dabhoi reduces the cost by Rs.50 lakhs to Rs. 60 lakhs per quarter.
๐Ÿ‘‰Mgmt's view on "bromobenzene" - It had already supplied 100 tons of bromobenzene in November to China. The pricing of this product is around $5.7 to $6/kg with a margin of $1.2.
๐Ÿ‘‰@ 100% capacity utilization of Bromobenzene, Co. is expected a revenue of about Rs 100 Cr.
๐Ÿ‘‰Mgmt vision of achieving a target revenue of Rs.1000 Crores in next five years.
๐Ÿ‘‰Co. has almost achieved import substitution for HMDS and CMIC.
๐Ÿ‘‰Mgmt is planning to discontinue the DHT & CBC products as they were not able to penetrate into the supply chain
Disc. - Technically, Holding tracking qty @ 325 with strict SL 260 WCB. Will review after Q3 results.
Thanksโ˜บ๏ธ
--END--

Loading suggestions...